FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038631078> ?p ?o ?g. }

• W3038631078 endingPage "e1463" @default.
• W3038631078 startingPage "e1457" @default.
• W3038631078 abstract "Abstract Lessons Learned Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes. Background Malignant mesothelioma is an aggressive disease for which few effective therapies are available. The Aurora family kinases are critical for mitotic fidelity and highly expressed in mesothelioma, wherein their inhibition leads to growth arrest in vitro. We evaluated the efficacy of alisertib, an Aurora A kinase inhibitor, in relapsed malignant mesothelioma. Methods Twenty-six patients with previously treated, unresectable pleural or peritoneal mesothelioma were enrolled on a single-arm, single-institution phase II trial of alisertib at a dosage of 50 mg twice daily for 7 of every 21 days. The primary endpoint was 4-month disease control rate. Secondary endpoints included overall response rate, progression free survival, overall survival, safety/toxicity, and correlation of endpoints with MYC copy number. Results Of the 25 evaluable patients treated on study, 8 (32%) experienced 4-month disease control, surpassing the futility endpoint. There were no confirmed partial or complete responses. Median progression-free and overall survival were 2.8 months and 6.3 months, respectively. No associations between MYC copy number and outcomes were observed. Conclusion Alisertib has modest activity in this unselected malignant mesothelioma population. Several patients achieved durable disease control. Although the study did meet its prespecified futility endpoint, the sponsor elected to close the trial at the interim analysis." @default.
• W3038631078 created "2020-07-10" @default.
• W3038631078 creator A5001218798 @default.
• W3038631078 creator A5007909021 @default.
• W3038631078 creator A5010884206 @default.
• W3038631078 creator A5017187936 @default.
• W3038631078 creator A5025719568 @default.
• W3038631078 creator A5041062966 @default.
• W3038631078 creator A5041570474 @default.
• W3038631078 creator A5042586171 @default.
• W3038631078 creator A5048380048 @default.
• W3038631078 creator A5057281549 @default.
• W3038631078 creator A5073466449 @default.
• W3038631078 date "2020-07-19" @default.
• W3038631078 modified "2023-10-18" @default.
• W3038631078 title "A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma" @default.
• W3038631078 cites W1886278373 @default.
• W3038631078 cites W1981073960 @default.
• W3038631078 cites W2029409133 @default.
• W3038631078 cites W2069910776 @default.
• W3038631078 cites W2079788104 @default.
• W3038631078 cites W2113897115 @default.
• W3038631078 cites W2116565287 @default.
• W3038631078 cites W2123766085 @default.
• W3038631078 cites W2125600615 @default.
• W3038631078 cites W2145685078 @default.
• W3038631078 cites W2150014472 @default.
• W3038631078 cites W2215044613 @default.
• W3038631078 cites W2399797906 @default.
• W3038631078 cites W2981636558 @default.
• W3038631078 cites W3013538909 @default.
• W3038631078 doi "https://doi.org/10.1634/theoncologist.2020-0610" @default.
• W3038631078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7543335" @default.
• W3038631078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32608142" @default.
• W3038631078 hasPublicationYear "2020" @default.
• W3038631078 type Work @default.
• W3038631078 sameAs 3038631078 @default.
• W3038631078 citedByCount "7" @default.
• W3038631078 countsByYear W30386310782021 @default.
• W3038631078 countsByYear W30386310782022 @default.
• W3038631078 countsByYear W30386310782023 @default.
• W3038631078 crossrefType "journal-article" @default.
• W3038631078 hasAuthorship W3038631078A5001218798 @default.
• W3038631078 hasAuthorship W3038631078A5007909021 @default.
• W3038631078 hasAuthorship W3038631078A5010884206 @default.
• W3038631078 hasAuthorship W3038631078A5017187936 @default.
• W3038631078 hasAuthorship W3038631078A5025719568 @default.
• W3038631078 hasAuthorship W3038631078A5041062966 @default.
• W3038631078 hasAuthorship W3038631078A5041570474 @default.
• W3038631078 hasAuthorship W3038631078A5042586171 @default.
• W3038631078 hasAuthorship W3038631078A5048380048 @default.
• W3038631078 hasAuthorship W3038631078A5057281549 @default.
• W3038631078 hasAuthorship W3038631078A5073466449 @default.
• W3038631078 hasBestOaLocation W30386310781 @default.
• W3038631078 hasConcept C126322002 @default.
• W3038631078 hasConcept C141071460 @default.
• W3038631078 hasConcept C142724271 @default.
• W3038631078 hasConcept C143998085 @default.
• W3038631078 hasConcept C203092338 @default.
• W3038631078 hasConcept C2776694085 @default.
• W3038631078 hasConcept C2777407522 @default.
• W3038631078 hasConcept C2778995398 @default.
• W3038631078 hasConcept C2780739268 @default.
• W3038631078 hasConcept C2908647359 @default.
• W3038631078 hasConcept C31760486 @default.
• W3038631078 hasConcept C535046627 @default.
• W3038631078 hasConcept C71924100 @default.
• W3038631078 hasConcept C99454951 @default.
• W3038631078 hasConceptScore W3038631078C126322002 @default.
• W3038631078 hasConceptScore W3038631078C141071460 @default.
• W3038631078 hasConceptScore W3038631078C142724271 @default.
• W3038631078 hasConceptScore W3038631078C143998085 @default.
• W3038631078 hasConceptScore W3038631078C203092338 @default.
• W3038631078 hasConceptScore W3038631078C2776694085 @default.
• W3038631078 hasConceptScore W3038631078C2777407522 @default.
• W3038631078 hasConceptScore W3038631078C2778995398 @default.
• W3038631078 hasConceptScore W3038631078C2780739268 @default.
• W3038631078 hasConceptScore W3038631078C2908647359 @default.
• W3038631078 hasConceptScore W3038631078C31760486 @default.
• W3038631078 hasConceptScore W3038631078C535046627 @default.
• W3038631078 hasConceptScore W3038631078C71924100 @default.
• W3038631078 hasConceptScore W3038631078C99454951 @default.
• W3038631078 hasIssue "10" @default.
• W3038631078 hasLocation W30386310781 @default.
• W3038631078 hasLocation W30386310782 @default.
• W3038631078 hasLocation W30386310783 @default.
• W3038631078 hasOpenAccess W3038631078 @default.
• W3038631078 hasPrimaryLocation W30386310781 @default.
• W3038631078 hasRelatedWork W104405473 @default.
• W3038631078 hasRelatedWork W1977676800 @default.
• W3038631078 hasRelatedWork W1988142118 @default.
• W3038631078 hasRelatedWork W1991175302 @default.
• W3038631078 hasRelatedWork W2018935093 @default.
• W3038631078 hasRelatedWork W2027083234 @default.
• W3038631078 hasRelatedWork W2117542219 @default.
• W3038631078 hasRelatedWork W2148707299 @default.
• W3038631078 hasRelatedWork W2360440123 @default.
• W3038631078 hasRelatedWork W3202034056 @default.

• next